Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
Last trade$0.5826
Day change-$0.0365 (-5.90%)
Day range$0.555 – $0.677
Volume214,649
Market cap$20M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$20.12M
Price / earnings
—
Price / book
-0.57×
Price / sales
1.08×
EV / sales
3.06×
EV / EBITDA
-1.34×
Profitability
Earnings per share
-$1.43
Return on assets
-48.15%
Return on equity
130.31%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.06×
Current ratio
0.11×
Quick ratio
0.1×
Cash ratio
0.01×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.92M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CELU, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$5.43M
$3.85M
$4.1M
$5.28M
$5.74M
$11.43M
$18.13M
$9.3M
Cost of revenue
$2.35M
$1.45M
$7.37M
$3.9M
$5.24M
$3.55M
$7.34M
$3.88M
Gross profit
$3.09M
$2.39M
-$3.27M
$1.38M
$494K
$7.87M
$10.79M
$5.41M
Selling, general and administrative
$4.94M
$9.17M
$15.06M
$9.31M
$12.63M
$14.26M
$16.06M
$12.65M
Research and development
$2.03M
$2.99M
$3.35M
$4.6M
$3.35M
$3.73M
$3.83M
$3.92M
Total operating expenses
$7.32M
$12.53M
$18.79M
$14.28M
$16.36M
$18.36M
$20.07M
$16.94M
Operating income
-$4.24M
-$10.13M
-$22.06M
-$12.9M
-$15.86M
-$10.49M
-$9.28M
-$11.53M
Interest expense
-$177K
-$352K
-$897K
-$1.48M
-$1.94M
-$2.44M
-$1.81M
-$1.75M
Income before taxes
$706K
$675K
-$24.36M
-$23.08M
-$24.52M
-$19.75M
-$13.29M
-$16.1M
Income taxes
$0
$0
$3K
$0
$0
$0
$0
$0
Net income
$706K
$675K
-$24.36M
-$23.08M
-$24.52M
-$19.75M
-$13.29M
-$16.1M
Net income attributable to common shareholders
$546K
$675K
-$24.45M
-$23.08M
-$24.52M
-$19.82M
-$13.29M
-$16.1M
EBITDA
-$2.7M
-$8.54M
-$20.2M
-$11.13M
-$14.03M
-$8.65M
-$7.6M
-$9.63M
Basic earnings per share
$0.02
$0.02
-$0.86
-$0.88
-$1.02
-$0.84
-$0.60
-$0.73
Diluted earnings per share
$0.02
$0.02
-$0.86
-$0.88
-$1.02
-$0.84
-$0.60
-$0.73
Recent news
Company coverage with links to the original publishers.
Celularity Inc. (Nasdaq: CELU) received a notification from Nasdaq on August 21, 2026, stating the company is not in compliance with listing rules due to failure to timely file its Quarterly Reports on Form 10-Q for periods ended June 30, 2026 and March 31, 2026. The company has until September 4, 2026 to submit a compliance plan, with a maximum 180-day grace period until November 16, 2026. Trading of the stock continues unaffected while the company works to complete and file the delayed reports.
Celularity Inc. received a notification from Nasdaq on May 27, 2026, indicating non-compliance with Listing Rule 5250(c)(1) due to delayed filing of its Quarterly Report on Form 10-Q for Q1 2026. The company has until July 28, 2026, to submit a compliance plan, with a potential extension until November 16, 2026. Trading of the stock continues unaffected, and the company is working to file the report and regain compliance.
NexGel (NASDAQ: NXGL) agreed to acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU). The transaction is expected to nearly triple NexGel's annual revenue to approximately $35 million in 2026 and make the company immediately profitable. The portfolio includes six commercial-stage products focused on tendon repair, skin grafts, and bone growth with over a decade of clinical use and existing insurance reimbursement pathways.
Celularity received a Nasdaq notification for not timely filing its Quarterly Report on Form 10-Q for June 30, 2025, potentially risking its listing compliance, with a deadline of September 5, 2025 to submit a compliance plan.
Celularity Inc. (CELU) announced that it did not timely file its Q1 2025 financial report, leading to a Nasdaq non-compliance notice. The company has 60 days to submit a plan to regain compliance and may be granted an extension until November 2025 if the plan is accepted.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.